(Press-News.org) Women who were either in the transition to menopause or postmenopausal experienced a reduction in the frequency and severity of menopausal hot flashes with the use of the antidepressant medication escitalopram, compared to women who received placebo, according to a study in the January 19 issue of JAMA.
"Hormonal agents have been the predominant therapy for menopausal hot flashes, but their use decreased substantially following the shifts in risk-benefit ratios that were identified in the Women's Health Initiative Estrogen plus Progestin randomized controlled trial. However, no other treatments have U.S. Food and Drug Administration approval for menopausal hot flashes, and the efficacy of alternative pharmacologic and nonpharmacologic agents is inconclusive," according to background information in the article. Selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs and SNRIs) have been investigated for hot flash treatment with mixed results. The SSRI escitalopram reduced hot flashes with minimal toxicities in 2 pilot investigations, but conclusions were limited by the small samples and unblinded treatment.
Ellen W. Freeman, Ph.D., of the University of Pennsylvania School of Medicine, Philadelphia, and colleagues evaluated the efficacy of escitalopram vs. placebo to reduce the frequency and severity of hot flashes in healthy women, and examined whether race, menopausal status, depressed mood, and anxiety were important modifiers of any observed effect. The multicenter, 8-week, randomized trial enrolled 205 women (95 African American; 102 white; 8 other) between July 2009 and June 2010. Women received 10 to 20 mg/d of escitalopram or a matching placebo for 8 weeks. The primary outcomes measured included frequency and severity of hot flashes assessed by prospective daily diaries at weeks 4 and 8.
The average frequency of hot flashes at the beginning of the study was 9.8 per day. Escitalopram was associated with a significant reduction in the frequency of hot flashes relative to placebo, adjusted for race, site, and baseline hot flash frequency. In the escitalopram group, average hot flash frequency at week 8 decreased to 5.26 hot flashes per day (47 percent decrease or an average of 4.6 fewer hot flashes per day than at the beginning of the study). In the placebo group, hot flash frequency decreased to 6.43 hot flashes per day (33 percent decrease or an average of 3.2 fewer hot flashes per day).
Clinical improvement at week 8 (decrease of 50 percent or more from baseline in hot flash frequency) was significantly greater in the escitalopram group than in the placebo group (55 percent vs. 36 percent). Also, use of escitalopram significantly reduced hot flash severity compared with placebo, adjusted for race, site, and baseline severity.
Race did not significantly modify the treatment effect. Overall discontinuation due to adverse events was 4 percent (7 in the active group, 2 in the placebo group).
"The 3-week postintervention follow-up demonstrated that hot flashes increased after cessation of escitalopram but not after cessation of placebo, providing further evidence of escitalopram's effects," the authors write.
The researchers note that although the decreases in hot flash frequency and severity appear modest, the study participants perceived these improvements as meaningful, as indicated by their reported satisfaction with treatment and desire to continue the treatment.
"Our findings suggest that among healthy women, 10 to 20 mg/d of escitalopram provides a nonhormonal, off-label option that is effective and well-tolerated in the management of menopausal hot flashes. Further studies are needed to directly compare the relative efficacy of SSRIs and SNRIs with hormone therapy in the treatment of menopause-related hot flashes."
###
(JAMA. 2011;305[3]:267-274. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Please Note: For this study, there will be multimedia content available, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 3 p.m. CT Tuesday, January 18 at www.digitalnewsrelease.com/?q=jama_3773.
To contact Ellen W. Freeman, Ph.D., call Olivia Fermano at 215-349-5653 or email olivia.fermano@uphs.upenn.edu.
For More Information: Contact the JAMA/Archives Media Relations Department at 312-464-JAMA or email: mediarelations@jama-archives.org.
END
Older adults without dementia and with lower levels in plasma of the biomarkers beta-amyloid 42/40 (protein fragments) had an increased rate of cognitive decline over a period of 9 years, according to a study in the January 19 issue of JAMA. The researchers also found that this relationship was stronger among individuals with less education and lower levels of literacy.
An estimated 36 million people currently have dementia, with the prevalence expected to double every 20 years, according to background information in the article. "Thus, biomarkers to identify elderly ...
Preliminary research suggests that use of a type of molecular imaging procedure may have the ability to detect the presence of beta-amyloid in the brains of individuals during life, a biomarker that is identified during autopsy to confirm a diagnosis of Alzheimer disease, according to a study in the January 19 issue of JAMA.
"Both diagnosis and treatment of Alzheimer disease (AD) are hampered by the lack of noninvasive biomarkers of the underlying pathology. Between 10 percent and 20 percent of patients clinically diagnosed with AD lack AD pathology at autopsy, and community ...
EAST LANSING, Mich. – The downsides of China's explosive urbanization – like pollution and greenhouse gas emissions – now are joined by an upside: Better environmental citizens.
It's the first time scientists have weighed employment and leadership when considering environmental behavior in China's cities. In the latest online edition of the British journal Environmental Conservation, scientists at the Center for Systems Integration and Sustainability at Michigan State University and collaborators in the U.S. and China show that city size – especially the good jobs there ...
UCSF researchers have tackled a decade-long scientific conundrum, and their discovery is expected to lead to significant advances in using stem cells to treat genetic diseases before birth. Through a series of mouse model experiments, the research team determined that a mother's immune response prevents a fetus from accepting transplanted blood stem cells, and yet this response can be overcome simply by transplanting cells harvested from the mother herself.
"This research is really exciting because it offers us a straightforward, elegant solution that makes fetal stem ...
People with good jobs found in large cities are more likely to engage in pro-environmental activities. So says a new study of China's environmental behavior published this week in the British journal Environmental Conservation.
For the first time, scientists weighed employment and leadership when considering how people act regarding their natural surroundings. They found the status and political power of companies in cities such as Beijing, Shanghai and Tianjin strongly influence the conservation practices of their employees.
Moreover, the scientists found employees ...
Standardized screening rule for TB in people living with HIV in low income settings
In 2009, 1.7 million people died from TB— which translates to 4700 deaths a day—including 380, 000 people living with HIV. TB remains the most common cause of death in people living with HIV. This week in PLoS Medicine, Haileyesus Getahun (WHO) and colleagues report the development of a simple, standardized tuberculosis (TB) screening rule for resource-constrained settings, to identify people living with HIV who need further investigation for TB disease. The results of this study, which ...
HIV treatment programs in sub-Saharan Africa should routinely report mortality rates among patients who remain in the programs and those patients lost to follow-up, according to a study by Matthias Egger and colleagues from the International Epidemiologic Databases to Evaluate AIDS in East Africa, Western Africa, and Southern Africa that is published in this week's PLoS Medicine. As a substantial proportion of patients in HIV treatment programs are lost to follow-up, mortality estimates for patients in these programs can be severely underestimated, so this bias needs to ...
Despite the wide endorsement of and support for eHealth technologies, such as electronic patient records and e-prescribing, the scientific basis of its benefits—which are repeatedly made and often uncritically accepted—remains to be firmly established.
Furthermore, even for the eHealth technologies that have proven to be successful, there is little evidence to show that such tools would continue to be successful beyond the contexts in which they were originally developed. These are the key findings of a study by Aziz Sheikh (University of Edinburgh, Edinburgh, Scotland) ...
There is not enough evidence to recommend the widespread use of statins in people with no previous history of heart disease, according to a new Cochrane Systematic Review. Researchers say statins should be prescribed with caution in those at low risk of cardiovascular disease (CVD).
CVD is the most common cause of death, accounting for nearly a third of all deaths worldwide. Cholesterol-lowering statins are first line treatments for heart patients and the benefits are well established. However, there is less evidence that statins are beneficial for preventing heart problems ...
Tranexamic acid (TXA), a drug used to treat heavy menstrual periods, could save the lives of tens of thousands of bleeding accident victims each year and reduce combat deaths, say Cochrane researchers. The researchers carried out a systematic review of trials examining the effectiveness of tranexamic acid (TXA) in patients with bleeding after severe injury.
TXA is an inexpensive drug that reduces clot breakdown. It has been used for many years to reduce heavy menstrual bleeding and is often given during planned surgery to reduce the need for blood transfusion. However, ...
